BioClinica Acquires a Patient Recruitment Firm
BioClinica, Inc., a global provider of clinical trial management services, extended its offerings with the acquisition of MediciGroup, Inc., a global patient recruitment and retention firm. The acquisition includes MediciGlobal, Ltd. and Access to Patients, LLC. Medici also provides a lost-to-follow-up patient locate service that finds missing patients globally. BioClinica was taken private for $123 million in January 2013 by a joint venture between JLL Partners, Inc. and Ampersand Partners. As part of that deal, the firms paid an undisclosed amount for medical imaging company CoreLab Partners, Inc. and merged it with BioClinica. Financial terms for the MediciGroup deal were not disclosed.... Read More »Consolidation Continues in the CRO Market
Back in 2013 clinical research organizations (CROs) were hot commodities, with 20 transactions for the year (that’s big, for the CRO sector). That was the summer that Kohlberg Kravis Roberts (NYSE: KKR) acquired PRA International and then ReSearch Pharmaceutical Services. This year, CROs are still in investors’ sites, with seven trasactions announced to date. After visiting a few healthcare deal making conferences recently, we expect to see a few more in the coming months. Read More »Ventas Spins Off Ardent Health’s Hospital Operations
As expected, Ventas, Inc. (NYSE: VTR) transferred the majority of Ardent Health Service’s hospital operations to Equity Group Investments last week, in exchange for $475 million. Ventas retains the owned real estate of the 10 Ardent Health hospitals, which it acquired in April 2015 for $1.75 billion. Ventas retains a 9.9% interest, while EGI and current Ardent Health Services management share the remaining ownership stake. Read More »Eye Diseases Spur More M&A in July
At least three of the deals announced so far in July have targeted companies or compounds that treat eye diseases. The first was Biogen Inc. (NASDAQ: BIIB) and its $124 million deal with Applied Genetic Technologies (NASDAQ: AGTC) for the worldwide commercialization rights to one clinical-stage and one pre-clinical therapeutic program. Last week, Allergan Inc. (NYSE: AGN) paid $125 million for Oculeve, Inc., a medical device company focused on new technologies for dry eye disease. Then, rival Valeant Pharmaceuticals International (NYSE: VRX) paid an undisclosed amount for the global rights to EyeGate Pharmaceuticals’ (OTCQB: EYEG) EyeGate II Delivery System and EGP-437 combination product... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
